Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10), FiscalAI reports. The business had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%.
Here are the key takeaways from Axsome Therapeutics’ conference call:
- Second-quarter revenue rose 46% year over year to $218 million, led by AUVELITY sales of $180.3 million, up 51%, and SUNOSI revenue growth of 20%.
- AUVELITY’s launch in Alzheimer’s disease agitation and expanded sales force are showing encouraging early indicators, including a 126% increase in new-to-brand prescriptions among patients aged 65 and older during the first eight weeks and 89% overall payer coverage.
- SYMBRAVO demand increased 30% sequentially to approximately 23,500 prescriptions, while SUNOSI prescriptions grew 14% year over year and 8% sequentially, both outpacing their respective markets.
- The FDA accepted the NDA for AXS-12 in narcolepsy cataplexy with a May 1, 2027 action date; Axsome also plans to begin its AXS-05 smoking-cessation trial and expects binge-eating-disorder data from solriamfetol in the fourth quarter of 2026.
- The company reported a $51.3 million quarterly net loss, while SG&A increased to $208.1 million due to commercialization investments; AUVELITY and SUNOSI gross-to-net discounts remained near 50%, and SYMBRAVO discounts temporarily rose into the high-80% range.
Axsome Therapeutics Stock Performance
Shares of AXSM stock opened at $220.89 on Tuesday. The stock has a market capitalization of $11.37 billion, a PE ratio of -59.22 and a beta of 0.65. Axsome Therapeutics has a 52-week low of $102.67 and a 52-week high of $260.19. The stock’s 50-day moving average price is $236.76 and its 200 day moving average price is $204.41. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27.
Insider Activity at Axsome Therapeutics
Hedge Funds Weigh In On Axsome Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after buying an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after acquiring an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after acquiring an additional 84,151 shares during the period. Caxton Associates LLP acquired a new position in shares of Axsome Therapeutics during the first quarter worth about $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. TD Cowen upped their target price on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Friday, July 17th. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective on shares of Axsome Therapeutics in a report on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft set a $280.00 target price on Axsome Therapeutics in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $265.55.
Check Out Our Latest Research Report on AXSM
Axsome Therapeutics News Summary
Here are the key news stories impacting Axsome Therapeutics this week:
- Positive Sentiment: Management indicated a potentially significant development cadence, targeting approximately one new drug application (NDA) annually through 2030. AXS-12, its narcolepsy candidate, is scheduled for a May 1, 2027 PDUFA date, providing a defined regulatory catalyst. Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA
- Positive Sentiment: Axsome’s commercial sales growth helped offset the quarterly earnings shortfall, supporting investor confidence in the company’s marketed-product base and revenue trajectory. Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss
- Positive Sentiment: The company’s second-quarter business update and presentation emphasized ongoing pipeline progress and corporate development, reinforcing the longer-term growth case for AXSM. Axsome Therapeutics Announces Q2 2026 Financial Results and Updates Corporate Presentation
- Neutral Sentiment: Second-quarter revenue was $218.38 million, close to—but below—the $221.11 million analyst consensus. Coverage is focused on whether key operating metrics and sales trends can sustain Axsome’s mid-cap growth profile. Axsome Q2 Earnings: What Key Metrics Have to Say
- Negative Sentiment: Axsome reported a second-quarter loss of $0.99 per share, wider than the $0.89 consensus estimate. The company remains unprofitable, with a negative net margin, so execution and progress toward sustainable earnings remain important risks. Axsome Therapeutics Second-Quarter Earnings Results
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome’s pipeline includes several late-stage and approved product candidates.
Featured Stories
- Five stocks we like better than Axsome Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
